Precision Medicine

Machina Medical's novel hydrogel barrier, MFUSE, gains FDA clearance, promising to control severe bleeding in seconds and disrupt the hemostasis market.

For 10 years, McKesson's QCDR has helped oncologists navigate MIPS. Now, new measures aim to elevate patient care and prove the value of treatment.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

The medtech firm reports a planned revenue decline as it divests its U.S. unit to partner Omnia Medical, betting on new tech applications for recovery.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Carrying the Alzheimer's gene, a longevity expert has turned himself into a public experiment, documenting his radical protocol to prevent the disease.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

A new fiber-optic platform combines laser delivery and temperature sensing, promising to reduce critical risks and enable next-generation medical devices.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

Genmab's antibody drug epcoritamab is the first of its kind to slow cancer progression in a Phase 3 trial for R/R DLBCL, offering a new path for patients.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

As dementia rates soar, one AI firm is using subtle signals from speech and drawing to spot cognitive decline years earlier, moving healthcare toward prevention.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

A landmark Nature Medicine publication for OrsoBio's TLC-2716 offers new hope for millions suffering from severe lipid and liver disorders.

Kaiser Permanente hires veteran strategist Beth Leonard for a new C-suite role, signaling a major push to influence policy and export its care model.

The global digital immunoassay market is set to triple, promising to find diseases earlier than ever. But can healthcare systems overcome the high cost?

Jennifer Erickson, a mentee of the retiring CEO, returns to lead Arizona's top lab, signaling a new era of innovation amid industry-wide shifts.

Basketball legends and the Prostate Cancer Foundation unite in a new initiative to fight late detection, urging men of color to prioritize life-saving screenings.

InterAx's AI platform and Alveus's R&D expertise combine in a new partnership to develop a next-gen obesity drug with durable results and better tolerability.